Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Boston, MassachusettsAges 18 years+ - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT07577206RecruitingEarly Phase 1
New PET Scan Tracer for Advanced Solid Cancers
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Naples, ItaliaAges 18 years+ - NCT07561437RecruitingEarly Phase 1
NK521 infusion for advanced cancer with fluid buildup
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT05417321RecruitingPhase 1/Phase 2
Test of HB0036 for advanced cancers that ran out of options
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Lafayette, IndianaAges 18 years+ - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07512583RecruitingPhase 1/Phase 2
TQB2930 injection for advanced solid tumors with HER2 expression
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06686745RecruitingPhase 1
Study of an experimental drug alone and with combination for advanced solid tumors
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06772415RecruitingPhase 1
Study of GenSci122 for advanced solid tumors
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07459998RecruitingPhase 1/Phase 2
SKB103 study for advanced solid tumors
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT07448116RecruitingPhase 1/Phase 2
Testing MCLA-129 plus ensartinib for advanced solid tumors
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07408258RecruitingPhase 1
Safety and dosing study of ONC-783 for advanced solid tumors
This trial tests an experimental drug called ONC-783 for people with advanced pancreatic, ovarian, colorectal, or breast cancer. The goal is to see if the drug is safe, how it works in the body, and whether it can help shrink tumors.
New York, New YorkAges 18 years+ - NCT07414316RecruitingEarly Phase 1
GK01 cell therapy for advanced lung or esophageal cancer
This trial tests a new cell treatment called GK01 for people with advanced lung cancer or esophageal cancer that has not responded to standard treatments. The study aims to see if this therapy can help shrink tumors or slow the cancer's growth.
NanchangAges 18–75 - NCT07413328RecruitingPhase 1
HWS116 for advanced solid tumors
This trial tests an experimental drug, HWS116, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07380386RecruitingPhase 1/Phase 2
SKB105 injection for advanced solid tumors
This trial tests a new drug called SKB105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07382544RecruitingPhase 1
Study of BMS-986504 with olaparib for MTAP-loss cancers
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
Houston, TexasAges 18 years+ - NCT07377591RecruitingPhase 1
Study of HDM2006 for advanced solid tumors
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.